Home Cancer Genetics and Molecular Tumor Testing Comprehensive Genomic Profiling Test: Cancer Genes, Mutations, and Results

Comprehensive Genomic Profiling Test: Cancer Genes, Mutations, and Results

By
Vita Library
-
30
Understand comprehensive genomic profiling results, tissue and liquid testing, actionable mutations, MSI, TMB, possible germline findings, limitations, and treatment matches.

Comprehensive genomic profiling examines many cancer-related genes and multiple types of genomic alteration in one test. It is most often used for advanced solid tumors when several targeted therapies, tumor-agnostic treatments, or clinical trials could depend on the molecular result. Depending on the platform, the test may detect substitutions, insertions and deletions, copy-number changes, gene fusions, microsatellite instability, tumor mutational burden, and selected signatures such as homologous recombination deficiency.

A broad report can uncover an approved treatment biomarker, explain resistance, refine a diagnosis, or suggest a clinical trial. It can also return variants with no proven clinical meaning, possible inherited findings that require germline confirmation, and a negative result despite a biologically driven cancer. “Comprehensive” does not mean that every gene, alteration, biomarker, or tumor cell has been assessed. The value of testing depends on specimen quality, panel design, timing, disease setting, available therapies, and expert interpretation. Results should be reviewed alongside pathology, imaging, prior treatment, performance status, and patient goals rather than used as an automated drug list.

  • Comprehensive genomic profiling usually analyzes hundreds of genes and several alteration classes at once.
  • The strongest result is a validated biomarker linked to an approved therapy in the patient’s exact cancer and setting.
  • A negative profile does not prove that the tumor lacks a driver or that no targeted therapy exists.
  • Tumor-only testing can reveal a possible inherited variant but cannot confirm germline status.
  • Molecular tumor board review can help resolve complex, rare, or conflicting findings.

Table of Contents

What Comprehensive Genomic Profiling Includes

Comprehensive genomic profiling, or CGP, is a broad form of tumor testing based mainly on next-generation sequencing. Unlike a single-gene test that asks whether one specific alteration is present, CGP evaluates many genes simultaneously and is designed to capture several biologically important alteration types.

A tissue CGP panel may report:

  • Single-nucleotide variants, such as BRAF V600E
  • Small insertions and deletions, such as EGFR exon 19 deletions
  • Copy-number gains or amplifications, such as ERBB2 amplification
  • Homozygous deletions or other copy-number losses
  • Structural variants and gene fusions, such as NTRK, RET, ALK, or ROS1 fusions
  • Splice alterations, including MET exon 14 skipping when RNA or validated DNA methods are used
  • Microsatellite instability, or MSI
  • Tumor mutational burden, or TMB
  • Selected genomic signatures, such as homologous recombination deficiency or loss of heterozygosity

No platform detects all of these equally well. Some assays analyze DNA only. Others combine DNA and RNA, which can improve fusion and splice-variant detection and show whether a rearranged gene is expressed. Whole-exome or whole-genome approaches cover more sequence than fixed panels but may not have the same depth for low-frequency variants.

CGP is broader than many routine biomarker panels, but the term has no single universal gene count. One commercial assay may evaluate 300 genes and another more than 500. A larger panel is not automatically better. The relevant questions are whether the assay covers the alteration types required for that tumor, has adequate analytical validation, and reports evidence in a clinically usable way.

The test describes the cancer genome at a particular time and from a particular specimen. Tumors evolve under treatment, and different metastases can contain different clones. An archival primary tumor may not show a resistance alteration that developed years later.

CGP is a type of tumor molecular profiling. It should not be confused with germline hereditary cancer testing, gene-expression recurrence assays, cytogenetic karyotyping, or multi-cancer early detection screening.

The report often separates biomarkers with treatment implications from other pathogenic alterations and VUS findings. It may also describe tumor purity, sequencing depth, quality-control metrics, and limitations. Those technical details determine how much confidence to place in a “not detected” result.

When CGP Is Considered

CGP is most useful when a broad result could change treatment. Professional recommendations support multigene NGS for several advanced cancers with multiple established biomarkers, including many non-squamous non-small-cell lung cancers, prostate cancers, colorectal cancers, cholangiocarcinomas, ovarian cancers, and other diseases in which molecular selection is standard.

Common indications include:

  • Newly diagnosed advanced or metastatic cancer with several actionable biomarkers
  • A rare tumor with uncertain or limited standard options
  • Cancer of unknown primary when molecular findings may support diagnosis or therapy
  • Progression after targeted treatment, when resistance mechanisms are suspected
  • An insufficient prior workup that tested only one or two genes
  • Eligibility assessment for a biomarker-selected clinical trial
  • A tumor type with an approved tumor-agnostic therapy based on MSI, TMB, NTRK fusion, RET fusion, BRAF V600E, or another qualifying biomarker
  • A young patient or unusual cancer in whom a possible hereditary finding would affect care

The best timing is often early enough that the result can inform a treatment decision. Ordering CGP only after a patient is too unwell for another therapy limits its clinical value. In cancers with urgent first-line biomarker requirements, testing should begin at diagnosis and may be combined with rapid single-gene or small-panel assays when turnaround is critical.

CGP is not required for every localized cancer. Many early-stage tumors are treated effectively according to pathology, stage, receptor testing, and validated disease-specific assays. Broad sequencing may find interesting alterations without evidence that acting on them improves outcome. The likelihood of benefit depends on cancer type, stage, and access to matched drugs or trials.

A focused assay can be preferable when one biomarker is needed urgently, tissue is extremely limited, or a validated companion diagnostic is required. Conversely, sequential single-gene tests can consume more tissue and time than one broad panel when many biomarkers are relevant.

Testing should consider the patient’s goals and ability to receive additional treatment. A report listing phase I trials in distant locations may offer little practical benefit if travel is impossible. Discuss expected yield, turnaround, costs, insurance coverage, tissue requirements, and the plan for possible germline findings before ordering.

CGP can also support diagnosis in selected tumors. Certain fusions, mutations, or methylation patterns are characteristic of specific entities. Molecular evidence must still be integrated with morphology and immunohistochemistry; sequencing alone does not replace pathology.

Tissue, Blood, and Paired Testing

Tissue is the standard specimen for many CGP assays. Formalin-fixed, paraffin-embedded blocks from surgery or biopsy are common. The pathologist selects a section with sufficient viable tumor and may mark an area for macrodissection to enrich tumor cells. Fresh, frozen, cytology, bone, and other specimens are accepted only if the laboratory has validated them.

The specimen should be recent enough to reflect current disease, especially after targeted therapy. An older untreated sample can still identify stable founding drivers, but it may miss acquired resistance. A new biopsy may be justified when histologic transformation is possible or the previous specimen is exhausted.

Decalcified bone specimens can be problematic. Strong-acid decalcification damages DNA and RNA, leading to failure or false-negative results. If a bone metastasis is the only accessible site, the team should coordinate with pathology to use an EDTA-based method or reserve material for molecular testing.

Blood-based CGP analyzes circulating tumor DNA in plasma. It is useful when biopsy is unsafe, tissue is insufficient, or rapid reassessment is needed. Plasma can sample DNA from several metastatic sites and reveal heterogeneity. Its principal limitation is sensitivity: a tumor that sheds little DNA can produce a false-negative result. A negative plasma test should be followed by tissue testing when feasible and when the missing result could change care.

Tissue and plasma can be complementary rather than competing. Tissue confirms histology, measures tumor content, and often detects copy-number changes and fusions more reliably. Plasma is less invasive and easier to repeat. Discordance may reflect low shedding, clonal evolution, sampling of different lesions, or clonal hematopoiesis.

Tumor-only testing compares tumor sequence with a population reference but not with the patient’s normal DNA. Paired tumor-normal testing sequences both tumor and a non-tumor sample, often blood. Pairing helps separate somatic from germline variants, filter clonal hematopoiesis, and improve interpretation, although it may not be available on every platform.

A blood “normal” sample requires caution in leukemia, lymphoma, clonal hematopoiesis, or after allogeneic stem-cell transplantation. The sample may contain malignant or donor-derived DNA. Cultured skin fibroblasts or another non-hematopoietic source may be needed.

Before sending material, the oncology team should ask the pathologist whether the block has enough tumor, whether other required tests need tissue, and whether repeat biopsy would provide a safer or more informative specimen.

How the Laboratory Performs the Test

The laboratory extracts DNA and, for some assays, RNA from the specimen. It measures quantity and quality, prepares sequencing libraries, enriches the selected gene regions, and sequences millions of fragments. Bioinformatic software aligns reads to a reference genome, identifies differences, estimates allele fractions and copy number, and filters technical artifacts.

Hybrid-capture methods can cover broad regions and detect diverse alteration types. Amplicon-based methods use targeted PCR and can be fast with low input, but coverage and fusion detection depend on primer design. Unique molecular identifiers help correct sequencing errors and improve confidence at low variant fractions.

RNA sequencing can confirm expressed fusions and detect splice changes that DNA panels miss. It is particularly valuable in tumors enriched for kinase fusions, such as some lung, thyroid, sarcoma, and pediatric cancers. RNA is more fragile than DNA, so old or poorly fixed tissue may fail RNA quality control even when DNA succeeds.

Analytical sensitivity depends on tumor percentage and sequencing depth. A heterozygous mutation in a specimen with 20% tumor may appear around 10% VAF, but copy-number changes, purity, and subclonality alter this relationship. Laboratories set minimum tumor-content recommendations and variant-reporting thresholds.

Copy-number analysis requires normalization across many genomic regions and can be less reliable in low-purity samples. Fusion detection depends on intronic coverage or RNA expression. TMB and MSI calculations differ by panel size and algorithm. Homologous recombination deficiency scores are assay- and cancer-specific.

Quality-control failure can occur because of low tumor content, necrosis, melanin, mucin, decalcification, poor fixation, tiny biopsy size, or degraded nucleic acid. A failure is not a negative result. Options include retesting another block, enriching tumor, using a focused assay, or obtaining plasma or new tissue.

Turnaround is commonly one to four weeks. Complex paired testing or tissue retrieval can take longer. Urgent treatment should not be delayed when a standard therapy is indicated and the genomic result is unlikely to change the immediate plan.

A validated clinical assay should disclose covered genes, reportable regions, alteration classes, limits of detection, reference genome, transcript selection, and regulatory status. The NGS method is only one part of the test; specimen handling, software, variant curation, and reporting are equally important.

How to Read the Report

Begin with the specimen and diagnosis. Confirm that the tested block came from the expected patient, tumor, site, and date. Note whether it represents the primary cancer, a metastasis, or plasma. Review tumor purity, quality warnings, and whether RNA testing succeeded.

Next, identify the highest-evidence findings. Reports may use AMP/ASCO/CAP tiers, ESCAT levels, FDA levels, proprietary categories, or another system. Although labels differ, they generally separate biomarkers with approved clinical utility from findings supported by trials, preclinical evidence, or uncertain significance.

A result may include:

  • Actionable pathogenic alteration: a driver with an approved therapy, guideline recommendation, or strong trial evidence
  • Resistance alteration: a change linked to reduced sensitivity to a current or proposed treatment
  • Diagnostic or prognostic alteration: a finding that helps classify disease or estimate behavior but does not select a drug
  • Variant of uncertain significance: insufficient evidence for clinical action
  • No reportable alteration: nothing meeting the assay’s thresholds, not proof of a mutation-free tumor
  • Indeterminate or failed result: inadequate quality or insufficient material

Read the exact variant. Different alterations in the same gene can have opposite effects. An activating ERBB2 mutation is not the same as ERBB2 amplification; a BRAF V600E mutation differs from a non-V600 class 2 or class 3 variant; an exon deletion may be pathogenic while a missense VUS is not.

Variant allele fraction can suggest clonality but is not definitive. A high VAF may reflect a clonal driver, amplification, loss of the normal allele, germline origin, or high tumor purity. A low VAF may represent a small resistant clone, low purity, or artifact near the detection threshold.

Review negative findings that were clinically required. If the report says “no actionable alterations,” verify that the assay adequately assessed all standard biomarkers for that cancer, including fusions, copy-number changes, MSI, and RNA-dependent events. A separate FISH, immunohistochemistry, PCR, or RNA assay may still be needed.

Clinical-trial suggestions change rapidly and may be generated automatically. Eligibility requires confirmation of cancer type, stage, prior therapy, organ function, location, and open enrollment. A listed trial is not a treatment recommendation.

Do not act on a VUS. It may be reclassified as more data accumulate, but most VUS findings do not become actionable. Keep the report and ask whether the laboratory provides updates.

Treatment Matches and Clinical Actionability

The most compelling match is an alteration detected by an appropriate assay and linked to an approved therapy for the same tumor type, disease stage, and treatment line. Some drugs require a specific companion diagnostic. Others accept a broader validated test under professional guidance.

Tumor-agnostic approvals apply across several cancer types when a defined biomarker is present, but they still have conditions. The patient may need advanced disease, no satisfactory alternatives, a specific age, or prior treatment. Evidence can vary among tumor types even under the same approval.

Off-label matches require more judgment. A drug effective against a mutation in lung cancer may not work in colon cancer because tissue context and parallel pathways differ. BRAF V600E is a classic example: effective combinations vary by cancer type. The gene name alone is insufficient.

Actionability frameworks rank evidence. ESCAT tier I generally represents alterations ready for routine use in a specific setting, while lower tiers indicate investigational or hypothetical value. AMP/ASCO/CAP systems similarly distinguish strong clinical significance from potential significance and VUS findings. The report should explain which disease and evidence support each match.

Co-alterations matter. A targetable driver may coexist with a resistance mutation or tumor-suppressor loss that changes response. The alteration may be subclonal and present in only part of the cancer. Prior therapies, drug interactions, brain penetration, organ function, and toxicity also affect whether a matched drug is suitable.

Matched treatment does not guarantee benefit. Many patients with an actionable finding cannot receive the drug because of prior therapy rules, access, declining health, or lack of a nearby trial. Others receive a match but do not respond. CGP expands options; it does not replace clinical judgment.

A molecular tumor board brings together oncologists, pathologists, geneticists, pharmacists, bioinformaticians, and trial specialists. Review is especially useful for rare variants, unusual tumor types, conflicting assays, multiple possible matches, or potential germline findings. The board may recommend confirmatory testing or a more evidence-supported option than the report’s automated list.

When no high-level target is found, standard therapy may still be highly effective. A negative profile should not be interpreted as “nothing can be done.” Chemotherapy, immunotherapy, radiation, surgery, hormonal therapy, and supportive care are selected by the full clinical picture.

Germline Findings, TMB, MSI, and Other Biomarkers

Tumor CGP can identify a variant in a hereditary cancer gene, but it cannot establish whether the variant is inherited. A BRCA1, BRCA2, PALB2, ATM, mismatch-repair, TP53, APC, RB1, VHL, RET, or other predisposition-gene finding may be somatic, germline, or both. Confirmation requires a dedicated germline sample, consent, and genetic counseling.

A high allele fraction, young age, multiple primary cancers, or suggestive family history increases suspicion but is not conclusive. Some germline variants have low tumor allele fractions, and some somatic variants appear near 50%. Laboratories may flag findings according to gene-specific criteria.

MSI-high or mismatch-repair-deficient tumors accumulate insertion and deletion errors at repetitive DNA sequences. MSI can support immunotherapy selection in qualifying settings and may prompt Lynch syndrome evaluation. The CGP result should be compared with mismatch-repair immunohistochemistry, tumor type, and germline testing when indicated.

TMB estimates the number of qualifying somatic mutations per megabase of analyzed DNA. It is an imperfect surrogate for tumor neoantigen load. Results depend on panel size, gene content, filtering, germline subtraction, and cutoff. A value labeled “high” on one assay may not be interchangeable with another. Treatment decisions should follow the validated assay and approved indication.

Homologous recombination deficiency describes impaired repair of double-strand DNA breaks. Panels may assess pathogenic BRCA1/2 alterations, genomic scars, loss of heterozygosity, or composite scores. The predictive value varies by ovarian, prostate, breast, pancreatic, and other cancers, and a generic HRD label should not be applied across diseases without validation.

Mutational signatures can suggest ultraviolet exposure, tobacco carcinogens, mismatch-repair deficiency, polymerase proofreading defects, or homologous recombination deficiency. They may support interpretation but are influenced by sequencing breadth and tumor purity. Many targeted panels are too small for reliable signature analysis.

Gene-expression, protein expression, and epigenetic biomarkers are not fully captured by DNA CGP. PD-L1 immunohistochemistry, hormone receptors, HER2 protein testing, methylation classifiers, and RNA-expression assays may be required separately. A broad DNA result does not supersede these tests.

Possible germline findings should be discussed before testing so the patient can decide how much inherited-risk information they wish to receive and how it may affect relatives.

Limitations and Questions for the Oncology Team

CGP can miss an alteration because it lies outside covered regions, occurs below the detection threshold, is difficult for the platform, or is absent from the sampled clone. Low tumor purity, damaged nucleic acid, and old tissue reduce sensitivity. A negative result is strongest only when specimen and assay quality were adequate for every relevant alteration class.

The test may produce information without an available intervention. Actionable rates reported in studies often include clinical trials or off-label drugs; the proportion who actually receive and benefit from matched therapy is lower. Access, cost, geography, and performance status create disparities.

Reports also become outdated. Drug approvals, trial status, variant classifications, and resistance evidence change. Reanalysis can be appropriate at progression or after a major update, especially if the original test was several years old or used a small DNA-only panel.

Useful questions include:

  • Why is broad profiling appropriate for this cancer and treatment stage?
  • Was tissue, plasma, or paired tumor-normal testing used?
  • Did the specimen meet tumor-content and quality requirements?
  • Which alterations and biomarkers were not assessed reliably?
  • Is the top finding linked to an approved therapy in this exact cancer and setting?
  • Does treatment require a specific companion diagnostic or confirmatory test?
  • Are any findings resistance markers or only VUS results?
  • Should RNA sequencing, FISH, immunohistochemistry, or another assay be added?
  • Could any result be inherited, and should germline testing be arranged?
  • Is a molecular tumor board or clinical-trial review available?
  • Would repeat tissue or plasma testing at progression add information?
  • What costs, turnaround time, and access barriers apply to the proposed treatment?

CGP should be used to refine a clinical plan, not to generate treatment by algorithm alone. A clear report links each finding to evidence, notes assay limitations, and distinguishes approved therapy from hypothesis.

Seek prompt medical evaluation for worsening symptoms regardless of the genomic report. Severe shortness of breath, neurologic change, uncontrolled pain, bleeding, jaundice, fever during treatment, or rapid decline requires clinical assessment and should not wait for sequencing results.

References

Disclaimer

This information is educational and does not replace individualized interpretation by an oncologist, pathologist, genetic counselor, or molecular tumor board. Assay coverage, evidence levels, drug approvals, and clinical-trial availability change over time and differ by jurisdiction. Do not start, stop, or select treatment solely from a comprehensive genomic profiling report without professional review.

RELATED ARTICLESMORE FROM AUTHOR